Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Dynavax Technologies Corporation is a biotechnology business based in the US. Dynavax Technologies Corporation shares (DVAX) are listed on the NASDAQ and all prices are listed in US Dollars. Dynavax Technologies Corporation employs 231 staff and has a trailing 12-month revenue of around USD$37.6 million.
|Latest market close||USD$5.06|
|52-week range||USD$1.8 - USD$12.44|
|50-day moving average||USD$4.7261|
|200-day moving average||USD$5.9862|
|Wall St. target price||USD$16|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.563|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||1.40%|
|1 month (2020-12-16)||9.29%|
|3 months (2020-10-15)||9.76%|
|6 months (2020-07-15)||-45.94%|
|1 year (2020-01-15)||-11.69%|
|2 years (2019-01-15)||-57.97%|
|3 years (2018-01-12)||15.75|
|5 years (2016-01-15)||21.05|
|Revenue TTM||USD$37.6 million|
|Gross profit TTM||USD$-37,284,000|
|Return on assets TTM||-15.77%|
|Return on equity TTM||-178.03%|
|Market capitalisation||USD$581.7 million|
TTM: trailing 12 months
There are currently 24.4 million Dynavax Technologies Corporation shares held short by investors – that's known as Dynavax Technologies Corporation's "short interest". This figure is 8.7% down from 26.7 million last month.
There are a few different ways that this level of interest in shorting Dynavax Technologies Corporation shares can be evaluated.
Dynavax Technologies Corporation's "short interest ratio" (SIR) is the quantity of Dynavax Technologies Corporation shares currently shorted divided by the average quantity of Dynavax Technologies Corporation shares traded daily (recently around 3.0 million). Dynavax Technologies Corporation's SIR currently stands at 8.11. In other words for every 100,000 Dynavax Technologies Corporation shares traded daily on the market, roughly 8110 shares are currently held short.
However Dynavax Technologies Corporation's short interest can also be evaluated against the total number of Dynavax Technologies Corporation shares, or, against the total number of tradable Dynavax Technologies Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Dynavax Technologies Corporation's short interest could be expressed as 0.22% of the outstanding shares (for every 100,000 Dynavax Technologies Corporation shares in existence, roughly 220 shares are currently held short) or 0.2961% of the tradable shares (for every 100,000 tradable Dynavax Technologies Corporation shares, roughly 296 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Dynavax Technologies Corporation.
Find out more about how you can short Dynavax Technologies Corporation stock.
We're not expecting Dynavax Technologies Corporation to pay a dividend over the next 12 months.
Dynavax Technologies Corporation's shares were split on a 1:10 basis on 10 November 2014. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Dynavax Technologies Corporation shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Dynavax Technologies Corporation shares which in turn could have impacted Dynavax Technologies Corporation's share price.
Over the last 12 months, Dynavax Technologies Corporation's shares have ranged in value from as little as $1.8 up to $12.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Dynavax Technologies Corporation's is 1.3984. This would suggest that Dynavax Technologies Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19; and collaboration with Medicago to develop a novel adjuvanted COVID 19 vaccine candidate. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Emeryville, California.
Everything we know about the Home Point Capital Inc IPO, plus information on how to buy in.
Everything we know about the ALFI INC IPO, plus information on how to buy in.
Steps to owning and managing CDAY, with 24-hour and historical pricing before you buy.
Steps to owning and managing CPF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CFFI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPY, with 24-hour and historical pricing before you buy.
Steps to owning and managing BANF, with 24-hour and historical pricing before you buy.
Steps to owning and managing AVDL, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing AUDC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.